Pictor, Mobility Health join forces

Biotech firm Pictor has collaborated with US laboratory service provider Mobility Health to launch a new antibody test, PictArray SARS-CoV2 antibody test.

Pictor secured a $6.1m investment to support the commercialisation and development of the new antibody test and other in vitro diagnostics of the company.

The funding round was led by former Morrison & Co CEO Marko Bogoievski and specialist growth investor K One W One (K1W1).

Pictor’s PictArray will indicate whether patients require a Covid-19 booster. It will facilitate efficient and customised Covid-19 assessments by detecting if a patient has antibodies from a previous infection of SARS-CoV-2 or vaccination alone.

The test will also identify whether at-risk individuals, despite vaccination or infection, failed to establish a detectable antibody response.

Pictor chief medical officer Tadd Lazarus said: “The PictArray SARS-CoV-2 Antibody Test is a high performance, all-in-one, NP/SP Covid-19 antibody test with serological differentiation.

“This is the only known test that separately measures antibodies from vaccines and SARS-CoV-2 infection in one test. The separate detection of SP and NP enables more precise clinical intervention.”

With an ability to distinguish between natural and vaccination-based antibodies, the test is an advancement with critical applications including vaccine development, said the firm.

Pictor CEO Howard Moore said: “Pictor is pleased to partner with Mobility Health to offer such a unique and important test.

“We are also incredibly grateful to Marko Bogoievski and Sir Stephen Tindall’s investment company K1W1 for their leadership in this investment.

“We now have the capital for further market development and launches within the United States, India, Australia, New Zealand, and the EU.”

Mobility Health founder and CEO Sandra Gunselman said: “This best-in-class technology offers each patient a personalized status of his or her protection against Covid-19.

“This is an important new tool in the enduring fight against Covid-19 and advances our mission of providing access to innovative new products.”

The investment round also saw participation from 20 other investors which will take the Pictor’s overall capital raised to $17m. NS Medical Devices